Drugmaker VIVUS has been struggling lately; initial sales from the launch of its obesity drug Qsymia failed to impress investors, and that resulted in a big drop in November. Today, however, shares were up by 4%. Could this be a sign that Qsymia sales are finally moving in the right direction?
In this video, Motley Fool health care analysts Max Macaluso and Brenton Flynn discuss what may be behind the share-price bump, and how it may affect not only VIVUS, but also some of the company's biggest competitors -- namely Arena Pharmaceuticals and Orexigen .
If you're looking for more information on both of these companies, grab copies of our premium research reports on Arena Pharmaceuticals and VIVUS today. In the reports, our senior biotech analyst, Brian Orelli, Ph.D. breaks down each company's strengths and weaknesses and explains the critical issues you need to know about. News in this space moves fast, so both reports come with a full year of updates. To learn more about Arena and VIVUS, click here today.
The article Is This the Start of a VIVUS Comeback? originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.